<DOC>
	<DOCNO>NCT00367185</DOCNO>
	<brief_summary>In multiple myeloma , combination chemotherapy melphalan plus prednisone use since 1960s regarded standard care elderly patient . We assess whether addition thalidomide combination adapt high-dose chemotherapy , use melphalan 100 mg/m2 -based regimen , would improve survival .</brief_summary>
	<brief_title>Treatment Newly Diagnosed Elderly Patients With Multiple Myeloma</brief_title>
	<detailed_description>Trial design This multicenter , randomize , control trial conduct French Myeloma Intergroup ( IFM ) elderly patient previously untreated multiple myeloma . The primary objective study compare efficacy safety MP MP-Thalidomide MEL100 ( intermediate-dose melphalan 100 mg/m2 - base treatment ) . The secondary objective compare efficacy MP-Thalidomide v MEL100 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Stage II III multiple myeloma accord Durie Salmon criterion . Patients 65 75 year age Previously untreated patient Prior history another neoplasm ( except basocellular cutaneous cervical epithelioma ) Primary associate amyloidosis World Health organisation performance index least 3 Significant renal insufficiency creatinine serum level 5.0 mg per deciliter Cardiac hepatic dysfunction Cerebral circulatory insufficiency Absolute contraindication corticosteroid Peripheral neuropathy HIV hepatitis B C positivity Patients geographic , social psychological condition might prevent adequate followup</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Elderly patient</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Autologous transplantation</keyword>
</DOC>